# Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

> **NCT06478212** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 51 (actual)

## Conditions studied

- IDH1-mutant Glioma
- IDH2-mutant Glioma

## Interventions

- **DRUG:** Vorasidenib
- **DRUG:** Temozolomide (TMZ)

## Key facts

- **NCT ID:** NCT06478212
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-22
- **Primary completion:** 2027-11
- **Final completion:** 2028-06
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06478212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06478212, "Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06478212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*